Tomás Chivato Martín-Falquina

Mr. Tomás Chivato Martín-Falquina

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2023 in Allergy
Verified
Journal Article
Open access
Jean BousquetJean Bousquet
Jean Bousquet
EME. Melén
E. Melén
THT. Haahtela
T. Haahtela
GKG. H. Koppelman
G. H. Koppelman
ATAlkis Togias
Alkis Togias
Josep M. BoquéJosep M. Boqué
Josep M. Boqué
Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one‐airway‐one‐disease,” coined over 20 years ago, is a simplistic approach of the links between upper‐ and lower‐airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper‐ and lower‐airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one‐airway‐one‐disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll‐Like Receptors and IL‐17 for rhinitis alone as a local disease; IL‐33 and IL‐5 for allergic and non‐allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono‐ or pauci‐sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.

18 November 2022 in Clinical and Translational Allergy
Verified
Journal Article
Open access
BSBernardo Sousa-Pinto
Bernardo Sousa-Pinto
AAAram Anto
Aram Anto
MBMarkus Berger
Markus Berger
SDStephanie Dramburg
Stephanie Dramburg
OPOliver Pfaar
Oliver Pfaar
Jean BousquetJean Bousquet
Jean Bousquet
Digital health is an umbrella term which encompasses eHealth and benefits from areas such as advanced computer sciences. eHealth includes mHealth apps, which offer the potential to redesign aspects of healthcare delivery. The capacity of apps to collect large amounts of longitudinal, real‐time, real‐world data enables the progression of biomedical knowledge. Apps for rhinitis and rhinosinusitis were searched for in the Google Play and Apple App stores, via an automatic market research tool recently developed using JavaScript. Over 1500 apps for allergic rhinitis and rhinosinusitis were identified, some dealing with multimorbidity. However, only six apps for rhinitis (AirRater, AllergyMonitor, AllerSearch, Husteblume, MASK‐air and Pollen App) and one for rhinosinusitis (Galenus Health) have so far published results in the scientific literature. These apps were reviewed for their validation, discovery of novel allergy phenotypes, optimisation of identifying the pollen season, novel approaches in diagnosis and management (pharmacotherapy and allergen immunotherapy) as well as adherence to treatment. Published evidence demonstrates the potential of mobile health apps to advance in the characterisation, diagnosis and management of rhinitis and rhinosinusitis patients.

23 September 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JBJuan de Dios Berná-Serna
Juan de Dios Berná-Serna
FGFlorentina Guzmán-Aroca
Florentina Guzmán-Aroca
JGJose Antonio Garcia-Vidal
Jose Antonio Garcia-Vidal
DHDolores Hernández-Gómez
Dolores Hernández-Gómez
AGAna Azahara García-Ortega
Ana Azahara García-Ortega
JBJuan de Dios Berná-Mestre
Juan de Dios Berná-Mestre
The aim of this study was to investigate the usefulness of platelet-rich plasma (PRP) treatment for chronic wounds (CWs) of the breast. A prospective study was performed in 23 patients with CW of the breast who were treated with PRP. The procedure was repeated until the wound was closed completely. The study included patients with a history of breast cancer (n = 8) and patients without cancer (n = 15). The treatment with PRP was successful in all cases and observed in ≤4 weeks in 82.6% (19/23) of patients. The patients without breast cancer showed significantly less time for wound closure than the patients with a history of breast cancer. Moreover, a greater number of PRP treatments were necessary to achieve wound closure in patients undergoing conservative breast treatment. No patients had complications associated with the application of PRP. Conclusions: To the best of our knowledge, this is the first study to reveal that PRP treatment for CWs of the breast is safe, simple, useful and well-tolerated by patients.

4 March 2025 in Radiation Physics and Chemistry
Verified
Journal Article
Closed access
EOElena Miñana Olmo
Elena Miñana Olmo
TMTomás Chivato Martín-Falquina
Tomás Chivato Martín-Falquina

8 April 2026 in Epidemiologia
Verified
Journal Article
Open access
PDF file
TMTomás Chivato Martín-Falquina
Tomás Chivato Martín-Falquina
JZJose Javier Zamorano-Leon
Jose Javier Zamorano-Leon
Ana Lopez-de-AndresAna Lopez-de-Andres
Ana Lopez-de-Andres
LFLUCIA FUENTES
LUCIA FUENTES
RGRodrigo Jiménez Garcia
Rodrigo Jiménez Garcia
Background/Objectives: Diabetes is associated with an increased risk of influenza-related complications; therefore, annual vaccination constitutes an essential preventive measure. The objective of this study is to analyze the evolution of influenza vaccination coverage among the population with diabetes in Spain between 2020 and 2023 and to identify factors associated with adherence, comparing it with a matched population without diabetes. Methods: A cross-sectional study was conducted using data from the European Health Survey in Spain 2020 and the Spanish National Health Survey 2023, applying 1:1 matching by age, gender, and place of residence. Multivariable logistic regression was applied to assess time trend and to identify adherence predictors. Results: Vaccination coverage among individuals with diabetes increased from 52.0% in 2020 to 65.9% in 2023 and was higher than that observed among the matched participants without diabetes in both periods. Older age and the presence of comorbidities, such as myocardial infarction or respiratory diseases, were associated with a higher likelihood of vaccination, whereas alcohol consumption and smoking were associated with lower adherence among subjects with diabetes. The year 2023 was independently associated with a higher probability of vaccination compared with 2020 (OR: 1.82; 95% CI: 1.56–2.12). Conclusions: Although influenza vaccination coverage among the Spanish people with diabetes has improved following the COVID-19 pandemic, it remains below recommended targets, highlighting the need to strengthen targeted strategies aimed at less adherent subgroups.

15 September 2023 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
EOElena Miñana Olmo
Elena Miñana Olmo
TMTomás Chivato Martín-Falquina
Tomás Chivato Martín-Falquina
Platelet kinetic parameters predict the efficiency of splenectomy in patients with immune thrombocytopenia. The multiple hit model is recommended to calculate the mean platelet survival time. This method involves complex formulae and iterative calculations that need specialized software, but currently available programs present some drawbacks. A new optimized solution is proposed. A Python 3 based computer program was developed in order to perform the multiple-hit model calculations. Validation was done by comparing its results to two additional programs, one using the Microsoft Excel solver add-in and the other fitting the curve by brute force. There was no difference in the results obtained by the three programs. The brute force program however took much longer times to achieve the results. The new program proved to be a fast, robust solution to determine the multiple-hit parameters needed to assess platelet kinetics.